Antallet af frafald grundet hændelser relateret til hypertension var heller ikke signifikant forskellig mellem lumiracoxib (37) og NSAID (52).
The number of discontinuations due to hypertension-related events was also not significantly different between lumiracoxib (37) and NSAIDs (52).